[New endovesical chemotherapy and means of administration: EMD, HIVEC, Synergo, Unithermia.]

Non-muscle invasive bladder cancer has a high recurrence and progression rate. Endovesical administration of chemotherapy after transurethral resection of bladder tumors aims to minimize the recurrence and progression rates. Over last decades BCG and MMC have been gold standard treatments. Still alarge proportion of patients recur and progress. Altogether with periods of BCG shortage has facilitate the search for alternatives. In the current manuscript we review the current drug sunder study including chemotherapy, immunotherapy and gene therapy. We also updated results on recent findings on means of intravesical administration, including hyperthermia assisted by external devices. The objectives of our products are implementing new efficient and safe alternatives and the development of technologies that increase of currently used drugs. After years without improvements in the field, nowadays we have a myriad of options available. Some of those new devices will remain and reach general urologist for their applicability. Preliminary results are promising and a positive environment surrounds the urologist in charge of bladder cancer.